Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Neutrophil lymphocyte ratio and duration of prior anti-angiogenic therapy as biomarkers in metastatic RCC receiving immune checkpoint inhibitor therapy

Fig. 1

Progression—free survival (PFS) estimates by (a) Heng prognostic score, (b) the duration of prior anti—VEGF inhibitors ≥6 months, and (c) pretherapy NLR. The median follow---up times are (a) NR (16.1,NR) months for ‘Low’ and 41.8 (19.0, NR) months for ‘Int/High’, (b) 41.8 (19.0,NR) months for ‘VEGF6 = 0’ and 16.1 (14.7,NR) months for ‘VEGF6 ≥ 1’, and (c) 41.8 (19.0,NR) months for ‘NLR < 3’ and NR (18.4,NR) months for ‘NLR ≥ 3’

Back to article page